181 related articles for article (PubMed ID: 31949930)
1. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
[TBL] [Abstract][Full Text] [Related]
2. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
3. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
4. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
[TBL] [Abstract][Full Text] [Related]
5. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer.
Choi YH; Lim Y; Ryu JK; Paik WH; Lee SH; Kim YT; Kim JH
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801891
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
7. Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature.
Averbuch I; Tschernichovsky R; Icht O; Goldstein DA; Mutai R; Dudnik E; Rotem O; Peled N; Allen AM; Laufer-Geva S; Goldberg Y; Zer A
Thorac Cancer; 2023 Jun; 14(17):1589-1596. PubMed ID: 37095004
[TBL] [Abstract][Full Text] [Related]
8. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
Pimenta JR; Ueda SKN; Peixoto RD
Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
[TBL] [Abstract][Full Text] [Related]
9. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
Park JH; Jo JH; Jang SI; Chung MJ; Park JY; Bang S; Park SW; Song SY; Lee HS; Cho JH
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008403
[TBL] [Abstract][Full Text] [Related]
10. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
11. Circulating
van der Sijde F; Azmani Z; Besselink MG; Bonsing BA; de Groot JWB; Groot Koerkamp B; Haberkorn BCM; Homs MYV; van IJcken WFJ; Janssen QP; Lolkema MP; Luelmo SAC; Mekenkamp LJM; Mustafa DAM; van Schaik RHN; Wilmink JW; Vietsch EE; van Eijck CHJ
Ther Adv Med Oncol; 2021; 13():17588359211033704. PubMed ID: 34422118
[TBL] [Abstract][Full Text] [Related]
12. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
Doroshow DB; O'Donnell PH; Hoffman-Censits JH; Gupta SV; Vaishampayan U; Heath EI; Garcia P; Zhao Q; Yu M; Milowsky MI; Galsky MD
JCO Precis Oncol; 2023 Jul; 7():e2300095. PubMed ID: 37410974
[TBL] [Abstract][Full Text] [Related]
13. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer.
Horiguchi S; Matsumoto K; Morimoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Tsutsumi K; Kato H
Acta Med Okayama; 2023 Oct; 77(5):517-525. PubMed ID: 37899263
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
Clin Cancer Res; 2017 Jul; 23(14):3610-3618. PubMed ID: 28137924
[No Abstract] [Full Text] [Related]
15. Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma.
Lecuelle J; Aarnink A; Tharin Z; Truntzer C; Ghiringhelli F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924443
[TBL] [Abstract][Full Text] [Related]
16. Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.".
Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
Urol Oncol; 2018 Jul; 36(7):345-346. PubMed ID: 29859727
[TBL] [Abstract][Full Text] [Related]
17. Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
Chabot C; Italiano A; Crombé A; Soubeyran I; Laizet Y; Khalifa E; Cousin S
Oncologist; 2024 May; 29(5):452-455. PubMed ID: 38558248
[TBL] [Abstract][Full Text] [Related]
18. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer.
Koay EJ; Katz MHG; Wang H; Wang X; Prakash L; Javle M; Shroff R; Fogelman D; Avila S; Zaid M; Elganainy D; Lee Y; Crane CH; Krishnan S; Das P; Fleming JB; Lee JE; Tamm EP; Bhosale P; Lee JH; Weston B; Maitra A; Wolff RA; Varadhachary GR
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914036
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
Pishvaian MJ; Blais EM; Brody JR; Rahib L; Lyons E; De Arbeloa P; Hendifar A; Mikhail S; Chung V; Sohal DPS; Leslie S; Mason K; Tibbets L; Madhavan S; Matrisian LM; Petricoin E
JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100730
[TBL] [Abstract][Full Text] [Related]
20. Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level.
Zimmermann MT; Mathison AJ; Stodola T; Evans DB; Abrudan JL; Demos W; Tschannen M; Aldakkak M; Geurts J; Lomberk G; Tsai S; Urrutia R
Front Oncol; 2021; 11():606820. PubMed ID: 33747920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
